Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Cogent Biosciences (COGT) Amortization of Deferred Charges (2017 - 2018)

Cogent Biosciences has reported Amortization of Deferred Charges over the past 2 years, most recently at $7000.0 for Q4 2018.

Quarterly results put Amortization of Deferred Charges at $7000.0 for Q4 2018, up 16.67% from a year ago — trailing twelve months through Dec 2018 was $23000.0 (up 15.0% YoY), and the annual figure for FY2025 was $601000.0, changed.
Amortization of Deferred Charges for Q4 2018 was $7000.0 at Cogent Biosciences, up from $5000.0 in the prior quarter.
Over the last five years, Amortization of Deferred Charges for COGT hit a ceiling of $7000.0 in Q4 2018 and a floor of $4000.0 in Q1 2017.